What does the trial data say about stopping semaglutide?
The most informative evidence on semaglutide maintenance comes from the STEP 1 extension study. After 68 weeks on semaglutide 2.4 mg weekly (during which participants lost an average of approximately 15% of body weight), participants who discontinued semaglutide and continued lifestyle counseling alone regained most of the weight within one year — an average of about two-thirds of what they had lost.
This result is often cited as evidence that semaglutide only works while you are taking it. That framing is accurate but incomplete. The same is true of most medications for chronic conditions. Blood pressure responds to antihypertensives while you take them. Blood glucose responds to metformin while you take it. Weight responds to semaglutide while you take it.
The clinical implication is that semaglutide for weight management is more appropriately framed as a long-term medication than a finite course, for most patients who want to maintain their results.
What does “maintenance dose” mean in clinical practice?
For brand-name Wegovy, the prescribing label targets 2.4 mg weeklyas the maintenance dose after the four-step titration (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16 weeks). The label does not define a lower maintenance option.
In clinical practice with compounded semaglutide, the picture is more flexible. Prescribing clinicians can adjust dose based on individual response. Some patients maintain their weight at doses lower than their peak titration dose — 1 mg weekly, for example, or 1.5 mg — once they have reached their goal weight. Others find that any reduction from peak dose leads to gradual regain within months.
This individual variability means there is no universally correct maintenance dose. The right dose is the lowest dose that maintains your specific result, determined empirically under clinician monitoring.
There is no universal maintenance dose — the right one is the lowest dose that holds your result, found by monitoring, not by a label.
What are the main approaches to semaglutide maintenance dosing?
Clinicians who manage semaglutide maintenance typically use one of several approaches:
| Approach | How it works | Best suited for |
|---|---|---|
| Hold at peak dose | Continue the dose used during active weight loss | Patients prioritizing regain prevention; those still seeing slow progress |
| Stepdown trial | After stabilizing 4–8 weeks at goal, reduce one increment (e.g., 2.4 mg → 1.7 mg); monitor 8–12 weeks and revert if regain begins | Patients who tolerated titration well and want to reduce side effects or cost |
| Frequency reduction | Reduce injection frequency (e.g., every 10 days instead of weekly) rather than per-dose amount | Some patients at maintenance; limited data — clinician judgment required |
| Discontinuation with monitoring | Stop completely with a defined weight threshold that triggers resumption | Patients who choose to stop; re-engagement plan is essential given regain data |
How does maintenance affect muscle mass?
GLP-1 medications drive weight loss through a combination of fat mass and lean mass reduction. Studies of semaglutide and tirzepatide have found that a meaningful portion of total weight lost comes from lean (muscle) mass, particularly in patients who do not maintain resistance training and adequate protein intake during treatment.
The maintenance phase is an important time to address this. Lower doses may be somewhat less muscle-depleting than peak doses, but the primary protective factors are behavioral: resistance exercise and protein targets. Some clinicians add adjunctive body composition support — including peptides like sermorelin — to maintenance protocols for patients concerned about lean mass preservation.
This is worth discussing with your prescribing clinician before beginning the maintenance phase, not after noticing muscle loss. Learn more about how PepScribe’s semaglutide programs are structured.
What should you monitor during semaglutide maintenance?
Active clinical monitoring during maintenance should include:
- Weight trend:Regular weigh-ins with a defined threshold for clinician contact. A 3–5% regain signal is a common trigger for a dose review.
- Body composition: Scale weight alone does not distinguish fat regain from lean mass changes. Body composition measurements (DEXA, impedance, or clinical assessment) at periodic intervals give a more complete picture.
- Metabolic labs: Fasting glucose, HbA1c where relevant, lipid panel. These are meaningful markers of whether the metabolic benefits achieved during active treatment are being maintained.
- GI tolerability: Side effects sometimes change at lower maintenance doses. Some patients experience improved tolerability; others find that dosing irregularity at maintenance re-introduces early side effects.
Compounded semaglutide for maintenance: practical considerations
Compounded semaglutide from a licensed US 503A pharmacy offers dose precision that brand-name formats do not. Where Wegovy pens come in fixed doses, compounded semaglutide can be prepared at the specific concentration that matches a lower maintenance dose precisely, without requiring the patient to use partial pens or non-standard administration.
Cost at maintenance doses is typically lower than peak-dose cost, since the per-unit drug cost tracks with dose. This makes compounded semaglutide maintenance more economically sustainable for patients whose primary financial concern was the cost of high-dose treatment.
All compounded semaglutide at PepScribe is prepared by licensed US 503A pharmacies with no hidden overseas supply chain. Clinician oversight continues through the maintenance phase, not just during initial titration.
Frequently asked questions
What is the maintenance dose for semaglutide?
There is no single standardized semaglutide maintenance dose. The FDA-approved label for Wegovy (semaglutide 2.4 mg) treats the 2.4 mg weekly dose as the target maintenance dose after titration. However, clinical practice with compounded semaglutide allows clinicians to prescribe lower maintenance doses based on individual patient response and tolerability.
Can I lower my semaglutide dose after reaching my goal weight?
Yes, with clinician oversight. Dose reduction is a reasonable consideration once you have reached your target weight. The practical question is whether the reduced dose maintains your result or leads to weight regain. This is an individual variable that requires clinical monitoring, not a blanket answer.
What happens if I stop semaglutide completely?
The STEP 1 extension study found that patients who discontinued semaglutide regained most of the weight lost within one year of stopping. This underscores that semaglutide addresses appetite signaling while being taken — it does not permanently reset weight physiology. Stopping without a plan is associated with significant regain.
How long do you stay on semaglutide maintenance?
Current evidence treats semaglutide for chronic weight management more like a long-term medication than a short course. The optimal duration is not established, and clinicians vary in how they approach this. Many patients who want to maintain their results continue at a maintenance dose indefinitely under ongoing clinical review.
Is compounded semaglutide available at maintenance doses?
Compounded semaglutide from a licensed US 503A pharmacy can be formulated at the concentration and volume that matches your prescribed maintenance dose. This is one advantage of compounded over brand-name formats — dose precision. A clinician prescription is required.
Does the semaglutide maintenance dose need to be the same as the peak dose?
Not necessarily. Some patients maintain their results at doses lower than the peak they reached during titration. Others find that stepping down leads to gradual regain. The right maintenance dose is determined empirically, through monitoring under clinician supervision.